A Phase I, Multicenter, Open-label, Dose Escalation Study of Intratumoral Injections of VCN-01 Oncolytic Adenovirus With Intravenous Gemcitabine and Abraxane in Advanced Pancreatic Cancer

Trial Profile

A Phase I, Multicenter, Open-label, Dose Escalation Study of Intratumoral Injections of VCN-01 Oncolytic Adenovirus With Intravenous Gemcitabine and Abraxane in Advanced Pancreatic Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs VCN 01 (Primary) ; Gemcitabine; Paclitaxel
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors VCN Biosciences
  • Most Recent Events

    • 31 Oct 2017 Planned End Date changed from 1 Apr 2017 to 1 Apr 2018.
    • 07 Jul 2016 Planned End Date changed from 1 Dec 2016 to 1 Apr 2017.
    • 07 Jul 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Oct 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top